CNS Drugs

, Volume 24, Issue 10, pp 829–841 | Cite as

Role of Pramipexole in the Management of Parkinson’s Disease

  • Angelo Antonini
  • Paolo Barone
  • Roberto Ceravolo
  • Giovanni Fabbrini
  • Michele Tinazzi
  • Giovanni Abbruzzese
Review Article


The non-ergot dopamine agonist pramipexole is currently indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease and for the treatment of moderate-to-severe primary restless legs syndrome. A new extended-release formulation of pramipexole has now also been launched in Europe and the US to improve ease of use, compliance and provide a more continuous therapeutic effect over 24 hours. Before initiating any treatment, the benefit-risk ratio to the individual patient must be considered. For pramipexole in the treatment of Parkinson’s disease, this means taking into account the available evidence regarding its symptomatic efficacy, effect on delaying long-term levodopa-related motor complications, beneficial effect on non-motor symptoms such as depression, and its safety and tolerability profile. Studies have shown that pramipexole is effective as monotherapy in early Parkinson’s disease and as adjunctive therapy in advanced disease. Trials further suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to the amelioration of depressive symptoms in Parkinson’s disease. Pramipexole is generally well tolerated; however, compared with levodopa treatment, pramipexole is associated with a higher rate of some dopaminergic adverse effects



Angelo Antonini has received honoraria for consulting services and symposia from Abbott, Boehringer Ingelheim, GlaxoSmithKline, Lundbeck, UCB, Novartis and Merck-Serono.

Gianni Abbruzzese has received honoraria for symposia from Novartis, Lundbeck, GlaxoSmithKline, UCB, Boehringer-Ingelheim and has been an advisory board member for Boehringer-Ingelheim.

Paolo Barone has received compensation for consulting services and research support from Boehringer Ingelheim, and payment for consulting services and symposia from Novartis, UCB, Merck-Serono, Eisai, Solvay, General Electric and Lundbeck.

Giovanni Fabbrini has received honoraria for symposia from Novartis, Lundbeck, GlaxoSmithKline and Boehringer-Ingelheim and has been an advisory board member for Boehringer-Ingelheim.

Roberto Ceravolo has received honoraria for symposia from Novartis, Lundbeck, GlaxoSmithKline, UCB and Boehringer-Ingelheim and has been on advisory boards for General Electric and Boehringer-Ingelheim.

Michele Tinazzi has received honoraria for Symposia and has been an advisory board member for Boehringer Ingelheim.

Editorial assistance (editing and referencing) was provided by Anita Chadha-Patel, PhD, who was supported by an unrestricted grant from the Neureca Foundation for movement disorders, Milan, Italy. No other sources of funding were used to prepare this review.


  1. 1.
    Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease 2009. Neurology 2009; 72(21 Suppl. 4): S1–136PubMedCrossRefGoogle Scholar
  2. 2.
    Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson’s disease: report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease. Eur JNeurol 2006; 13(11): 1170–85CrossRefGoogle Scholar
  3. 3.
    Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol 1998; 21(3): 141–51PubMedGoogle Scholar
  4. 4.
    Maj J, Rogoi Z, Margas W, et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Transm 2000; 107(12): 1369–79PubMedCrossRefGoogle Scholar
  5. 5.
    Wright CE, Sisson TL, Ichhpurani AK, et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997; 37(6): 520–5PubMedGoogle Scholar
  6. 6.
    Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur JNeurol 2000; 7 Suppl. 1: 15–20CrossRefGoogle Scholar
  7. 7.
    Jenner P, Konen-Bergmann M, Schepers C, et al. Pharmaco-kinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009;31(11): 2698–711PubMedCrossRefGoogle Scholar
  8. 8.
    Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol 1995; 18(4): 338–47PubMedCrossRefGoogle Scholar
  9. 9.
    Shannon KM, Bennett Jr JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease: the Pramipexole Study Group. Neurology 1997; 49(3): 724–8PubMedCrossRefGoogle Scholar
  10. 10.
    Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease: a randomized dose-ranging study. JAMA 1997; 278(2): 125–30CrossRefGoogle Scholar
  11. 11.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000; 284(15): 1931–8CrossRefGoogle Scholar
  12. 12.
    Navan P, Findley LJ, Jeffs JA, et al. Randomized, doubleblind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov Disord 2003; 18: 1324–31PubMedCrossRefGoogle Scholar
  13. 13.
    Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61(7): 1044–53PubMedCrossRefGoogle Scholar
  14. 14.
    Schrag A, Sampaio C, Counsell N, et al. Minimal clinically important change on the unified Parkinson’s disease rating scale. Mov Disord 2006; 21(8): 1200–7PubMedCrossRefGoogle Scholar
  15. 15.
    Noyes K, Dick AW, Holloway RG. Pramipexole versus levodopa in patients with early Parkinson’s disease: effect on generic and disease-specific quality of life. Value Health 2006; 9(1): 28–38PubMedCrossRefGoogle Scholar
  16. 16.
    Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009 May; 66(5): 563–70CrossRefGoogle Scholar
  17. 17.
    Chapuis S, Ouchchane L, Metz O, et al. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov Disord 2005; 20(2): 224–30PubMedCrossRefGoogle Scholar
  18. 18.
    Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa: 056 Study Group. N Engl J Med 2000; 342(20): 1484–91PubMedCrossRefGoogle Scholar
  19. 19.
    Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson’s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997; 48(2): 363–8PubMedCrossRefGoogle Scholar
  20. 20.
    Wermuth L. A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson’s disease. Eur J Neurol 1998; 5(3): 235–42PubMedCrossRefGoogle Scholar
  21. 21.
    Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162–8PubMedCrossRefGoogle Scholar
  22. 22.
    Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66(4): 436–41PubMedCrossRefGoogle Scholar
  23. 23.
    Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease: International Pramipexole-Bromocriptine Study Group. Neurology 1997; 49(4): 1060–5PubMedCrossRefGoogle Scholar
  24. 24.
    Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord 2003; 18(10): 1149–56PubMedCrossRefGoogle Scholar
  25. 25.
    Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord 2001; 7(2): 115–20PubMedCrossRefGoogle Scholar
  26. 26.
    Moller JC, Oertel WH, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord 2005; 20(5): 602–10PubMedCrossRefGoogle Scholar
  27. 27.
    Inzelberg R, Carasso RL, Schechtman E, et al. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson’s disease. Clin Neuropharmacol 2000; 23(5): 262–6PubMedCrossRefGoogle Scholar
  28. 28.
    Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72(6): 713–20PubMedCrossRefGoogle Scholar
  29. 29.
    Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6(6): 513–20PubMedCrossRefGoogle Scholar
  30. 30.
    Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl 2006; (71): 17–25CrossRefGoogle Scholar
  31. 31.
    Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson’s disease with cabergoline delays the onset of motor complications: results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 Suppl. 1:23–30PubMedCrossRefGoogle Scholar
  32. 32.
    Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5(8): 677–87PubMedCrossRefGoogle Scholar
  33. 33.
    Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol 2006; 2(7): 382–92PubMedCrossRefGoogle Scholar
  34. 34.
    Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov Disord 2004; 19(9): 997–1005PubMedCrossRefGoogle Scholar
  35. 35.
    Albrecht S, Buerger E. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole. Curr Med Res Opin 2009 Dec; 25(12): 2977–87PubMedCrossRefGoogle Scholar
  36. 36.
    Schapira AH. Neuroprotection in PD: a role for dopamine agonists? Neurology 2003; 61(6 Suppl. 3): S34–42PubMedCrossRefGoogle Scholar
  37. 37.
    Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004; 291(3): 358–64PubMedCrossRefGoogle Scholar
  38. 38.
    Carter AJ, Muller RE. Pramipexole, a dopamine D2 auto-receptor agonist, decreases the extracellular concentration of dopamine in vivo. Eur J Pharmacol 1991; 200(1): 65–72PubMedCrossRefGoogle Scholar
  39. 39.
    Le WD, Jankovic J, Xie W, et al. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm 2000; 107(10): 1165–73PubMedCrossRefGoogle Scholar
  40. 40.
    Carvey PM, Ling ZD. Pramipexole prevents levodopa-induced DA neurotoxicity in vitro implicating D3 receptors in neuroprotection [abstract]. Mov Disord 1996; 11 Suppl. 1: 179Google Scholar
  41. 41.
    Carvey PM, Pieri S, Ling ZD. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104(2-3): 209–28PubMedCrossRefGoogle Scholar
  42. 42.
    Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287(13): 1653–61CrossRefGoogle Scholar
  43. 43.
    Whone AL, Remy P, Davis MR, et al. The REAL-PET study: slower progression in early Parkinson’s disease treated with ropinirole compared with levodopa [abstract]. Neurology 2002; 58 Suppl. 3: A82Google Scholar
  44. 44.
    Ahlskog JE. Slowing Parkinson’s disease progression: recent dopamine agonist trials. Neurology 2003; 60(3): 381–9PubMedCrossRefGoogle Scholar
  45. 45.
    Jennings DL, Tabamo R, Seibyl JP, et al. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [123I]b-CIT and SPECT imaging. Mov Disord 2007; 22 Suppl. 16: 143Google Scholar
  46. 46.
    Schapira A, Albrecht S, Barone P, et al. Immediate vs delayed start pramipexole in early Parkinson’s disease: the PROUD study [abstract]. Parkinsonism Relat Disord 2009; 15 Suppl. 2: S81CrossRefGoogle Scholar
  47. 47.
    Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009; 361(13): 1268–78PubMedCrossRefGoogle Scholar
  48. 48.
    Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7): 996–1002PubMedCrossRefGoogle Scholar
  49. 49.
    Hughes TA, Ross HF, Mindham RH, et al. Mortality in Parkinson’s disease and its association with dementia and depression. Acta Neurol Scand 2004; 110(2): 118–23PubMedCrossRefGoogle Scholar
  50. 50.
    Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253(5): 601–7PubMedCrossRefGoogle Scholar
  51. 51.
    Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399–406PubMedCrossRefGoogle Scholar
  52. 52.
    Barone P, Poewe W, Tolosa E, et al. Efficacy of double-blind, placebo-controlled pramipexole against depression in Parkinson’s disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S347CrossRefGoogle Scholar
  53. 53.
    Leentjens AF, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivational symptoms in Parkinson’s disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009; 31(1): 89–98PubMedCrossRefGoogle Scholar
  54. 54.
    Lemke MR, Brecht HM, Koeste J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci 2006; 248(1-2): 266–70PubMedCrossRefGoogle Scholar
  55. 55.
    Antonini A, Tolosa E, Mizuno Y, et al. A reassessment of risks and benefits of dopamine agonists in Parkinson’s disease. Lancet Neurol 2009; 8(10): 929–37PubMedCrossRefGoogle Scholar
  56. 56.
    Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 2000; 57(5): 729–32PubMedCrossRefGoogle Scholar
  57. 57.
    Kleiner-Fisman G, Fisman DN. Risk factors for the development of pedal edema in patients using pramipexole. Arch Neurol 2007; 64(6): 820–4PubMedCrossRefGoogle Scholar
  58. 58.
    Biglan KM, Holloway Jr RG, McDermott MP, et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69(2): 187–95PubMedCrossRefGoogle Scholar
  59. 59.
    Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52(9): 1908–10PubMedCrossRefGoogle Scholar
  60. 60.
    Paus S, Brecht HM, Koster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord 2003; 18(6): 659–67PubMedCrossRefGoogle Scholar
  61. 61.
    Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287(4): 455–63PubMedCrossRefGoogle Scholar
  62. 62.
    Hauser RA, Gauger L, Anderson WM, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000; 15(4): 658–63PubMedCrossRefGoogle Scholar
  63. 63.
    Antonini A, Cilia R. Behavioral adverse effects of dopa-minergic treatment in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32:475–88PubMedCrossRefGoogle Scholar
  64. 64.
    Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 2007; 64(2): 212–6PubMedCrossRefGoogle Scholar
  65. 65.
    Weintraub D. Dopamine and impulse control disorders in Parkinson’s disease. Ann Neurol 2008; 64 Suppl. 2: S93–100PubMedCrossRefGoogle Scholar
  66. 66.
    Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95PubMedCrossRefGoogle Scholar
  67. 67.
    Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006; 66(11): 1750–2PubMedCrossRefGoogle Scholar
  68. 68.
    Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord 2008; 23(3): 411–5PubMedCrossRefGoogle Scholar
  69. 69.
    Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 2007; 6(9): 826–9PubMedCrossRefGoogle Scholar
  70. 70.
    Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007; 356(1): 39–46PubMedCrossRefGoogle Scholar
  71. 71.
    Müller T, Fritze J. Fibrosis associated with dopamine agonist therapy in Parkinson’s disease. Clin Neuropharmacol 2003; 26(3): 109–11PubMedCrossRefGoogle Scholar
  72. 72.
    Poewe W, Barone P, Hauser R, et al. Pramipexole extended-release is effective in early Parkinson’s disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S273Google Scholar
  73. 73.
    Schapira AH, Barone P, Hauser R, et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease [abstract]. Mov Disord 2009; 24 Suppl. 1: S277Google Scholar
  74. 74.
    Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson’s disease at the same daily dosage [abstract]. Mov Disord 2009; 24 Suppl. 1: S362Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Angelo Antonini
    • 1
    • 2
  • Paolo Barone
    • 3
  • Roberto Ceravolo
    • 4
  • Giovanni Fabbrini
    • 5
  • Michele Tinazzi
    • 6
  • Giovanni Abbruzzese
    • 7
  1. 1.Department for Parkinson DiseaseIRCCS San CamilloVeniceItaly
  2. 2.University of PaduaPaduaItaly
  3. 3.Department of Neurological SciencesIDC-Hermitage-CapodimonteNaplesItaly
  4. 4.Department of NeurosciencesUniversity of PisaPisaItaly
  5. 5.Department of Neurological Sciences and Neuromed InstituteSapienza University of RomeRomeItaly
  6. 6.Department of Neurological SciencesUniversity of VeronaVeronaItaly
  7. 7.Department of Neurosciences, Ophthalmology and GeneticsCentre for Movement Disorders, University of GenoaGenoaItaly

Personalised recommendations